Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 2 of 9 · 415 articles
Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term...
This reports preclinical Crohn’s disease research linking creeping fat to intestinal scarring and the creation of a mouse model to study fibrosis and test interventions — an early step toward therapies for strictures.
GLP-1 drugs are widely used for diabetes and weight loss; if trials show they reduce gut inflammation, they could become a new treatment option being tested against existing biologics.
GLP-1 drugs are being studied as possible treatments for gut conditions beyond weight loss—researchers are exploring whether they can reduce gut inflammation or improve related liver disease. Patients with IBD, IBS, or...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to...
Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Spatial transcriptomics helps map where genes are expressed in intestinal tissue, which can reveal cellular mechanisms of IBD and guide research. Knowing which platforms give more reliable data matters for multicenter...
Based on the title and source metadata, this appears to be an observational study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from pressreader.com.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from cureus.com.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the full details.
The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...
Some people with moderate-to-severe Crohn’s who don’t fully respond to one advanced therapy may hear about adding a second drug. This article explains when clinicians might consider that approach, the potential benefits...
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
New clinical results for TREMFYA in perianal fistulizing Crohn's disease and positive data for another J&J IBD drug could signal future treatment options or regulatory milestones that matter to people with Crohn's and...
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.
Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Research and clinical trials.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
If you had bowel surgery for Crohn’s disease and develop postoperative anastomotic bleeding, this study suggests endoscopic treatment can stop bleeding in most patients and may avoid another operation. Patients who need...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor.
Surgical technique after ileocolic resection may influence how likely Crohn’s disease is to come back near the anastomosis.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This report summarizes recent late-stage trial results, regulatory actions, and new biosimilar launches that could affect treatment options, availability, and drug costs in Crohn’s disease over the coming years.
Market shifts influence availability, cost, and development of new Crohn's disease treatments. Wider use of biosimilars and growth in biologics/small molecules can affect access and treatment choices over time.
This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.
This work targets a possible root cause (epithelial stress and cell death) rather than only suppressing inflammation — if validated in humans, it could offer new treatment options for people who don’t respond to current...
This study suggests a different treatment target for Crohn’s disease: fixing damaged intestinal lining rather than only suppressing inflammation. If validated in humans, repurposed cancer drugs could speed development of...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
This study suggests a new treatment angle for Crohn’s disease by targeting epithelial cell stress and barrier repair rather than only dampening immune inflammation. If validated in clinical trials, it could lead to...
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
The study identifies a specific protein interaction that may underlie persistent inflammation; for people with Crohn’s and other inflammatory conditions this points to a potential new, more targeted treatment approach in...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease and Research and clinical trials. The original article is from msn.com.
How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Imaging. Open the original article for the full details.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from msn.com.
Treg cell therapy aims to reduce harmful immune activity that drives Crohn's disease. If developed successfully, it could become a targeted cell-based treatment option for patients who don't respond to current therapies.
